Evidence map›Paper›PMID 40708813›Full record

ArticleIn vitro models2025

Multicellular hepatic in vitro models using NANOSTACKS

Abdullah C Talari, Raffaello Sbordoni, Valmira Hoti, Talha Jalil, Imran I Patel, Francis L Martin, Ahtasham Raza, Valon Llabjani

Abstract read
In one paragraph

Article in In vitro models, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Abdullah C TalariSci-Tech Daresbury, REVIVOCELL Limited, Keckwick Lane, Daresbury, Warrington WA4 4 AD UK.
Raffaello SbordoniSci-Tech Daresbury, REVIVOCELL Limited, Keckwick Lane, Daresbury, Warrington WA4 4 AD UK.
Valmira HotiSci-Tech Daresbury, REVIVOCELL Limited, Keckwick Lane, Daresbury, Warrington WA4 4 AD UK.
Talha JalilSci-Tech Daresbury, REVIVOCELL Limited, Keckwick Lane, Daresbury, Warrington WA4 4 AD UK.
Imran I PatelSci-Tech Daresbury, REVIVOCELL Limited, Keckwick Lane, Daresbury, Warrington WA4 4 AD UK.
Francis L MartinSci-Tech Daresbury, REVIVOCELL Limited, Keckwick Lane, Daresbury, Warrington WA4 4 AD UK.
Ahtasham RazaSci-Tech Daresbury, REVIVOCELL Limited, Keckwick Lane, Daresbury, Warrington WA4 4 AD UK.
Valon LlabjaniSci-Tech Daresbury, REVIVOCELL Limited, Keckwick Lane, Daresbury, Warrington WA4 4 AD UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug-induced liver injury (DILI) continues to be one of the leading causes of drug attrition during clinical trials, as well as the number one cause of post-market drug withdrawal due to the limited predictive accuracy of preclinical animals and conventional in vitro models. In this study, the NANOSTACKS

Indexed as

Complex in vitro modelsDrug-induced liver injury (DILI)Hepatic modelsNANOSTACKS™

Identifiers

PMID40708813
PMCPMC12283536

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.